Conor Killmurray

"The TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options," said Neeraj Agarwal, MD, FASCO.

The approval is based on findings from the phase 3 TALAPRO-2 trial.

The benefit in radiographic progression-free survival extended across all subgroups of patients with HRR-deficient metastatic castration-resistant prostate cancer.

The researchers combined machine learning and rule-based natural language processing to develop an algorithm that leveraged electronic health records to identify patients with nmCRPC.

Initial data from the phase 1/2a modular PETRA trial showed that the next-generation highly selective PARP1 inhibitor AZD5305 had comparable safety and promising clinical activity compared with first-generation PARP inhibitors.

The dual immunotherapy regimen maintained a survival benefit over single-agent sunitinib in patients with advanced renal cell carcinoma.